Drugs / zetomipzomib
zetomipzomib
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03393013 | Feb 2018 → Aug 2022 | lupus nephritis, systemic lupus erythematosus | Kezar Life Sciences, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05781750 | Nov 2023 → Nov 2024 | lupus nephritis | Kezar Life Sciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05569759 | May 2023 → Apr 2025 | autoimmune hepatitis | Kezar Life Sciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04628936 | Nov 2020 → Mar 2023 | dermatomyositis | Kezar Life Sciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04039477 | Jul → Aug 2020 | autoimmune hemolytic anemia, autoimmune thrombocytopenia | Kezar Life Sciences, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04033926 | Jan 2020 → Apr 2022 | dermatomyositis | Kezar Life Sciences, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zetomipzomib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05569759 ↗ |
| Known as | KZR-616 | “Zetomipzomib (KZR-616)” NCT05781750 ↗ |
| Known as | KZR-616 maleate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297468 ↗ |
| Known as | ZETOMIPZOMIB MALEATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297468 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4297468 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection of KZR-616” NCT03393013 ↗ |